Adverse events after treatment of patients with acute limb ischemia

Ann Vasc Surg. 2015 Feb;29(2):293-302. doi: 10.1016/j.avsg.2014.10.022. Epub 2014 Nov 28.

Abstract

Background: To assess the outcome and the occurrence and consequences of adverse events (AEs) after treatment of acute limb ischemia (ALI).

Methods: Retrospective analysis on intra-arterial thrombolysis (group I) and thromboembolectomy (group II). Outcome measures were primary patency and limb salvage rates. AEs and consequences were registered during admission and 30 days after discharge.

Results: A total of 238 procedures were included (group I, 173 vs. group II, 65). The primary patency (P = 0.144) and limb salvage rates (P = 0.166) were not significantly different between both groups. A total of 195 AEs were registered. Most AEs were procedure related and resulted in surgical reintervention (77% vs. 76%). Some AEs resulted in irreversible physical damage (15% vs. 25%) and death (6% vs. 12%).

Conclusions: Both, intra-arterial thrombolysis and thromboembolectomies are adequate therapies; however, they result in a wide variety of AEs resulting in serious morbidity and even death.

Publication types

  • Comparative Study

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Databases, Factual
  • Embolectomy / adverse effects*
  • Embolectomy / mortality
  • Extremities / blood supply*
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects*
  • Humans
  • Ischemia / diagnosis
  • Ischemia / mortality
  • Ischemia / physiopathology
  • Ischemia / therapy*
  • Kaplan-Meier Estimate
  • Limb Salvage
  • Male
  • Middle Aged
  • Postoperative Complications / etiology*
  • Postoperative Complications / mortality
  • Retrospective Studies
  • Risk Factors
  • Thrombectomy / adverse effects*
  • Thrombectomy / mortality
  • Thrombolytic Therapy / adverse effects*
  • Thrombolytic Therapy / mortality
  • Time Factors
  • Treatment Outcome
  • Vascular Patency / drug effects

Substances

  • Fibrinolytic Agents